Literature DB >> 33685409

Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.

Ming-Jeng Kuo1, Lein-Ray Mo2, Chi-Ling Chen3.   

Abstract

BACKGROUND: We quantified the elusive effects of putative factors on the clinical course of early hepatocellular carcinoma (HCC) after primary surgical or nonsurgical curative treatment.
METHODS: Patients with newly diagnosed early HCC who received surgical resection (SR) or percutaneous radiofrequency ablation (RFA) with or without transcatheter arterial chemoembolization (TACE) from January 2003 to December 2016 were enrolled. The cumulative overall survival (OS) and disease-free survival (DFS) rates were compared. A polytomous logistic regression was used to estimate factors for early and late recurrence. Independent predictors of OS were identified using Cox proportional hazard regression.
RESULTS: One hundred twenty-five patients underwent SR, and 176 patients underwent RFA, of whom 72 were treated with TACE followed by RFA. Neither match analysis based on propensity score nor multiple adjustment regression yielded a significant difference in DFS and OS between the two groups. Multivariate analysis showed high AFP (> 20 ng/mL), and multinodularity significantly increased risk of early recurrence (< 1 year). In contrast, hepatitis B virus, hepatitis C virus and multinodularity were significantly associated with late recurrence (> 1 year). Multivariate Cox regression with recurrent events as time-varying covariates identified older age (HR = 1.55, 95% CI:1.01-2.36), clinically significant portal hypertension (CSPH) (HR = 1.97, 95% CI:1.26-3.08), early recurrence (HR = 6.62, 95% CI:3.79-11.6) and late recurrence (HR = 3.75, 95% CI:1.99-7.08) as independent risk factors of mortality. A simple risk score showed fair calibration and discrimination in early HCC patients after primary curative treatment. In the Barcelona Clinic Liver Cancer (BCLC) stage A subgroup, SR significantly improved DFS compared to RFA with or without TACE.
CONCLUSION: Host and tumor factors rather than the initial treatment modalities determine the outcomes of early HCC after primary curative treatment. Statistical models based on recurrence types can predict early HCC prognosis but further external validation is necessary.

Entities:  

Keywords:  Early hepatocellular carcinoma; Prognosis; Propensity score matching; Radiofrequency ablation; Surgical resection; Transcatheter arterial chemoembolization

Mesh:

Year:  2021        PMID: 33685409      PMCID: PMC7941925          DOI: 10.1186/s12885-021-07948-9

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  48 in total

1.  Anatomic resection and wide resection margin play an important role in hepatectomy for hepatocellular carcinoma with peritumoural micrometastasis.

Authors:  Changying Shi; Qian Zhao; Boyi Liao; Zhitao Dong; Can Wang; Jiamei Yang; Weifeng Shen
Journal:  ANZ J Surg       Date:  2019-10-16       Impact factor: 1.872

2.  Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma.

Authors:  Davide Citterio; Antonio Facciorusso; Carlo Sposito; Roberta Rota; Sherrie Bhoori; Vincenzo Mazzaferro
Journal:  JAMA Surg       Date:  2016-09-01       Impact factor: 14.766

3.  A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma.

Authors:  Giuseppe Cabibbo; Salvatore Petta; Marco Barbàra; Gabriele Missale; Roberto Virdone; Eugenio Caturelli; Fabio Piscaglia; Filomena Morisco; Antonio Colecchia; Fabio Farinati; Edoardo Giannini; Franco Trevisani; Antonio Craxì; Massimo Colombo; Calogero Cammà
Journal:  Liver Int       Date:  2017-02-01       Impact factor: 5.828

4.  Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.

Authors:  Chun-Ying Wu; Yi-Ju Chen; Hsiu J Ho; Yao-Chun Hsu; Ken N Kuo; Ming-Shiang Wu; Jaw-Town Lin
Journal:  JAMA       Date:  2012-11-14       Impact factor: 56.272

Review 5.  Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus.

Authors:  Shoji Kubo; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Takahiro Uenishi
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

6.  Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.

Authors:  Margarita Sala; Josep M Llovet; Ramon Vilana; Lluís Bianchi; Manel Solé; Carmen Ayuso; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

Review 7.  Fibrosis reversal after hepatitis C virus elimination.

Authors:  Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2019-05       Impact factor: 3.287

8.  Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC.

Authors:  Arnaud Hocquelet; Christophe Aubé; Agnès Rode; Victoire Cartier; Olivier Sutter; Anne Frederique Manichon; Jérome Boursier; Gisèle N'kontchou; Philippe Merle; Jean-Frédéric Blanc; Hervé Trillaud; Olivier Seror
Journal:  J Hepatol       Date:  2016-07-13       Impact factor: 25.083

9.  Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy.

Authors:  Koichiro Yamakado; Atsuhiro Nakatsuka; Haruyuki Takaki; Hajime Yokoi; Masanobu Usui; Hiroyuki Sakurai; Shuji Isaji; Katsuya Shiraki; Hiroyuki Fuke; Shinji Uemoto; Kan Takeda
Journal:  Radiology       Date:  2008-02-27       Impact factor: 11.105

10.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

View more
  3 in total

1.  Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.

Authors:  Lan-Qing Yao; Zheng-Liang Chen; Zi-Han Feng; Yong-Kang Diao; Chao Li; Hai-Ying Sun; Jian-Hong Zhong; Ting-Hao Chen; Wei-Min Gu; Ya-Hao Zhou; Wan-Guang Zhang; Hong Wang; Yong-Yi Zeng; Han Wu; Ming-Da Wang; Xin-Fei Xu; Timothy M Pawlik; Wan Yee Lau; Feng Shen; Tian Yang
Journal:  Ann Surg Oncol       Date:  2022-02-22       Impact factor: 5.344

2.  Clinical Nursing Paths Benefit Patient Outcomes Undergoing Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.

Authors:  Jing Gu; Yao Liang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-20       Impact factor: 2.650

Review 3.  Transarterial Chemoembolization Combined With Radiofrequency Ablation Versus Hepatectomy for Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Yuan Dan; Wenjun Meng; Wenke Li; Zhiliang Chen; Yongshuang Lyu; Tianwu Yu
Journal:  Front Surg       Date:  2022-07-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.